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Abstract
In this article, the authors briefly review the historical evolution of the various putative precursor
lesions for Type II endometrial cancers, with an emphasis on the newly defined "Endometrial
Glandular Dysplasia (EmGD)". The evidentiary basis for delineating serous EmGD as the most
probable precursor lesions to endometrial serous carcinoma is reviewed in detail. An argument is
advanced for the discontinuation of the term serous "endometrial intraepithelial carcinoma (EIC)"
as a descriptor for a supposedly intraepithelial, precancerous lesion. Preliminary evidence is also
presented that suggests that there is a morphologically recognizable "clear cell EmGD" that
probably represents a precancerous lesion to endometrial clear cell carcinomas.
Background
Endometrial cancers are the most frequently diagnosed
malignancies of the female genital tract in the United
States, with 39,080 new cases projected for 2007 [1]. Since
1983, two broad clinicopathologic subtypes of endome-
trial carcinomas have been recognized [2]. This concep-
tual classification has largely been supported by
subsequent molecular-cytogenetic data, which has facili-
tated the acceptance of the so-called dualistic model of
endometrial carcinogenesis [3-8]. Type I cancers, the pro-
totype of which is the endometrioid histotype, occur in
comparatively younger age group [3-8], appear to be
related to unopposed estrogen stimulation [9-14], fre-
quently express the estrogen and progesterone receptors
[7,13,14], arise in a background of glandular hyperplasia
[5,7,13,14], and has a relatively favorable prognostic pro-
file [15]. Genetic alterations in Type 1 cancers include
PTEN inactivation [16-19], beta-catenin (CTNNB1) muta-
tions [17], and less frequently, microsatellite instability
(related to inactivation of the MLH1 gene) [20,21], and
activational mutations of the K-ras gene [22]. Type II can-
cers, the prototype of which is the endometrial serous car-
cinoma (ESC), and which was previously termed uterine
papillary serous carcinoma (UPSC), typically occur in an
older age group [3-8], frequently arise in a background of
inactive or resting endometrium [3-8], and display a low
frequency of expression of hormonal receptors
[13,14,23,24]. Type II cancers also display frequent muta-
tion and overexpression of the p53 [24-26] and HER2/
neu [27,28] genes and proteins respectively, and have a
comparatively poor prognosis independent of other fac-
tors [29-32]. This model has provided a valuable frame-
Published: 8 February 2008
Diagnostic Pathology 2008, 3:6 doi:10.1186/1746-1596-3-6
Received: 23 January 2008
Accepted: 8 February 2008
This article is available from: http://www.diagnosticpathology.org/content/3/1/6
© 2008 Fadare and Zheng; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Diagnostic Pathology 2008, 3:6 http://www.diagnosticpathology.org/content/3/1/6
Page 2 of 9
(page number not for citation purposes)
work for the study of various aspects of endometrial
carcinogenesis and for the potential development of ther-
apeutic modalities that are pathway specific. Nonetheless,
approximately 7400 deaths attributable to uterine corpus
malignancies are projected for 2007 [1]. This relatively
high mortality rate suggests that prevention and/or early
detection remain highly essential approaches to the pre-
vention of endometrial cancer-related mortality. One
aspect of cancer prevention is the recognition of morpho-
logically distinctive precursor lesions or "precancers" [33],
so that a therapeutic intervention can be administered
prior to the development of the well-developed malig-
nancy. For more than 100 years, scientists have noted a
spectrum of epithelial changes that have tentatively been
considered to be precancerous in nature based on one or
more of the following factors: a) the frequent coexistence
of the putative precursor lesions with the well-developed
malignancy as well as occasional morphologic transitions
between them b) Shared epidemiologic, patient demo-
graphical, immunophenotypic and/or molecular genetic
properties between the putative precursor lesions and
their associated well-developed malignancies, and c) Lon-
gitudinal follow-up data that suggests that the putative
precursor lesions confer an increased risk for the develop-
ment of invasive malignancies [24,26,32,34-88]. These
factors notwithstanding, the definition, full morphologic
spectrum (including upper and lower limits) and clinical
significance of the various putative endometrial precan-
cers remain controversial. One factor contributing to this
state of affairs is the ever-evolving nomenclature of
endometrial precancers, a significant impediment to com-
paring data between studies. The purpose of this com-
mentary is to summarize the current published data that
forms the basis for the recent delineation of Endometrial
Glandular Dysplasia (EmGD) as the most probable pre-
cancerous lesions for serous and probably clear cell carci-
nomas of the endometrium.
Serous endometrial glandular dysplasia
Reports describing variably papillary endometrial cancers
with psammoma bodies have appeared in the literature
since at least 1963 [89-93]. However, it was in the 1980
text by Hendrickson and Kempson that the concept of
"serous" differentiation and aggressive behavior in these
cancers was first emphasized [56]. Endometrial serous car-
cinomas (ESC) are now well recognized as uncommon
endometrial cancers with distinctive morphologic fea-
tures and a significantly worse overall survival as com-
pared their endometrioid counterparts [29-32,94]. In
1992, Sherman et al [32] described 32 uterine carcinomas
with a serous component, including 13 pure cases and 19
cases admixed with other histotypes. The authors noted
the existence of "cytologically malignant cells closely
resembling the invasive serous carcinoma in the surface
endometrium adjacent to the tumor" [32]. This lesion was
present in 89% of their 32 cases and was designated
"intraepithelial carcinoma" by the authors [32]. Two
reports published in 1995 appeared to be describing
essentially the same "intraepithelial" lesion [66,67].
Spiegel et al [67] reviewed 518 hysterectomy specimens
with endometrial cancers and found 89 cases "in which
there were microscopic foci of malignant epithelium that
failed to alter the architecture of an otherwise thin
atrophic or weakly proliferative endometrium or endome-
trial polyp [67]." Sixty-six percent of the cancers associ-
ated with these foci had a serous component, and the
author applied the designation "endometrial carcinoma
in situ" [67]. In a study published later that year, Ambros
et al [66] introduced the term "endometrial intraepithelial
carcinoma" (EIC), and showed that this lesion was fre-
quently and specifically associated with endometrial car-
cinomas with a serous component. In 1998, Zheng et al
[70] used the designation "uterine surface carcinoma" to
describe this lesion, noting that it is "often multicentric
and behaves in a more aggressive fashion than regular in
situ carcinomas" which rendered the previous designa-
tions inappropriate. In 2000, Wheeler et al [72] noted the
difficulties and questionable validity of distinguishing
EIC from stromal invasive but non-myoinvasive (superfi-
cial) ESC. The authors proposed the concept of "minimal
uterine serous carcinoma", a term that would combine
EIC, as previously defined [66], with small superficial ESC
(<1 cm). "Serous EIC" is the recommended designation in
the most recent WHO classification [88].
Pure serous EIC (serous EIC unassociated with a full
blown and/or myoinvasive serous carcinomas) may
potentially show extrauterine disease and/or peritoneal
carcinomatosis [73]. Shared patterns of p53 mutations
between the endometrial and extrauterine lesions argue in
support of true origination of the latter from the former
[74]. However, since pure serous EIC is so infrequently
identified in isolation, there are no systematically col-
lected data on precisely what percentage of them will
show extrauterine disease. Non-myoinvasive (stage 1A)
ESCs are known to show extrauterine disease in 17–67%
of cases [68,76,95,96].
In our opinion, the serous EIC designation, as used in this
context to describe a supposedly intraepithelial, precan-
cerous lesion, should be discarded. The notion that a "pre-
cancerous" lesion may display clinical malignancy (as
evidenced by extrauterine extension) is indicative to us of
a fundamental fallacy in the definition of the putative pre-
cursor lesion and is an obvious contradiction in terms.
The distinction between serous EIC (as presently defined)
and small "stromal-invasive" (stage 1A) ESC is a rather
artificial one that is largely devoid of clinical significance
and whose validity is questionable. Both are lined by
identical, cytologically malignant cells [32,66,67,70],Diagnostic Pathology 2008, 3:6 http://www.diagnosticpathology.org/content/3/1/6
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both may show extrauterine disease [68,76,95,96], and
both require comprehensive surgical staging
[68,76,81,95,96]. Rather, serous EIC is best conceptual-
ized, and should be clinically managed as, small or early
ESC [76]. Clement and Young [97] have outlined a similar
approach, writing that they consider EIC "a tiny focus of
serous carcinoma and do not qualify it further other than
to note its size and location". Although tumor size is a
well-established prognostic factor in malignancies of
many organ systems, it is unclear if a comparable signifi-
cance is operational in this particular malignancy, since
diffuse extrauterine dissemination has been associated
with microscopic endometrial lesions. However, one
would intuitively expect the large "malignancy burden" of
multifocal or extensive endometrial disease to increase the
probability of extrauterine extension. Until the signifi-
cance of lesion size is clarified, prudence should dictate
that lesion size and disease extent be noted in the patho-
logic report but only after properly classifying the lesion as
an ESC (rather than a serous EIC).
Given the aforementioned problems with serous EIC as a
biologically valid precancer, Zheng et al [79] hypothe-
sized that a morphologically identifiable lesion existed
that bridged the gap between resting endometrium, in
which ESC most frequently arises, and these so-called
serous EIC lesions. The authors examined 108 hysterecto-
mies (32 cases of classic ESC, 16 serous EIC, 60 endome-
trioid cancers). In 53% of the 32 cases of ESC and 1.7% of
the 60 endometrioid cancers (p < 0.0001) one or more
microscopic, morphologically atypical lesions that did
not qualify for a serous EIC designation were identified
[79]. These lesions were most commonly single glands or
small glandular groups within the superficial
endometrium or a flat layer of epithelium on the endome-
trial surface. These foci did not qualify for a serous EIC
designation because their level of atypia was consistently
not at the level seen in the adjacent well-developed serous
cancers, which is a definitional requirement for serous
EIC. These glands were designated "Endometrial Glandu-
lar Dysplasia" (EmGD) [79]. The typical EmGD focus
showed epithelium lined by cells with nucleomegaly (2–
4 times resting endometrium, as compared with 4–5
times in serous EIC), variably conspicuous nucleoli, vari-
able hyperchromasia and loss of nuclear polarity [79]
(Figure 1). Notably, the MIB-1 proliferative and p53 stain-
ing indices of the EmGD lesions were at least intermediate
between the resting endometrium and the serous EIC.
Based on their frequent and apparently specific associa-
tion with ESCs, as well as their "intermediate" morpho-
logic and immunophenotypic features (between benign
and malignant epithelium), the authors speculated that
EmGD represents the true precursor lesion of ESC [79], on
the presumption that endometrial serous carcinogenesis
is also a morphologically identifiable "stepwise process",
rather than the spontaneous or "de novo" arising of ESC
from benign endometrium. In a subsequent molecular
study, Liang et al [77] provided preliminary evidence that
suggested that although EmGD are not lined by compara-
bly cytologically malignant cells, they are closer to EIC/
ESC than to resting endometrium. The patterns of loss of
heterozygosity at 7 microsatellite polymorphic DNA
markers were investigated in laser microdissected areas of
EmGD and serous EIC/ESC. For 4 of the 7 markers, the
frequency of LOH was higher in EmGD lesions as com-
pared with resting endometrium, reaching statistical sig-
nificance in 2 (TP53 and D1S162) and approaching such
significance in the other 2 (D1S211 and D2S123). By con-
trast, when EmGD was compared to serous EIC/ESC, in
only 1 locus -TP53 – was the frequency of LOH signifi-
cantly different (31.3% in EmGD versus 60% in serous
EIC/ESC). Furthermore, in paired EmGD and serous EIC/
ESC samples (from the same patient), there was a high
degree of concordance in the frequency of LOH [77]. The
frequent mutation of the p53 gene in EmGD was con-
firmed in a subsequent study [98]. p53 mutations were
identified in 0%, 43%, 72%, and 96% of resting
endometrium, EmGD, serous EIC and ESC, respectively.
Furthermore, in excess of 50% of the uteri with the afore-
mentioned neoplastic lesions showed at least one identi-
cal p53 gene mutation among lesions of EmGD, serous
EIC and/or ESC [98,99]. These findings provide a molec-
ular link between EmGD and ESC, one of the basic tenets
of a putative precancer [33].
Recently, we investigated the endometrial biopsies that
preceded hysterectomies in which ESC were diagnosed in
an effort to determine whether EmGD lesions could be
identified and if so, to estimate the duration between the
diagnoses of the dysplastic and malignant lesions [82]. In
250 hysterectomies with ESC, preceding endometrial
biopsies were available for evaluation in 27 cases. Of these
27 cases, EmGD lesions were identified in 9 cases
(33.3%). The average duration between the biopsies in
which the EmGD lesions were identified and the hysterec-
tomies in which the ESCs were diagnosed was 33 months
(range 16–98 months). In the control group of 258 hys-
terectomies with benign diagnoses, only 1 EmGD was
identified out of 29 preceding endometrial biopsies that
were available for evaluation [82]. This provides prelimi-
nary evidence that EmGD may be associated with an
increased risk of ESC, another tenet of a precancer [33]. At
the protein level, the novel cytoplasmic marker IMP3
[Insulin-like growth factor II (IGF-II) mRNA binding Pro-
tein] provides further supportive evidence that links
EmGD and ESC. Among endometrial cancers, IMP3 pre-
dominantly marks ESC. Zheng et al [100] demonstrated
IMP3 expression is present in 14% of EmGD, 89% of
serous EIC and 94% of ESC. IMP3 expression was signifi-
cantly less frequent in the other lesions studied: 0 (0%) ofDiagnostic Pathology 2008, 3:6 http://www.diagnosticpathology.org/content/3/1/6
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35, 5 (7%) of 70, 0 (0%) of 8, 3 (25%) of 12, and 5 (33%)
of 15 cases of atypical hyperplasia, endometrioid, muci-
nous, clear cell carcinomas, and other malignancies,
respectively.
To summarize the data from our group 1) EmGD is a mor-
phologically identifiable, typically focal lesion that shows
an association with endometrial cancers displaying serous
differentiation [79]. 2) This association is common (53%
of hysterectomies with ESC) and apparently specific, at
least relative to endometrioid adenocarcinomas [EmGD
was seen in only 1.7% of hysterectomies with endometri-
oid cancers] [79] 3) EmGD are distinct from ESC/serous
EIC as they are lined by cells whose degree of atypia falls
short of the frankly malignant cells required of the latter;
there are typically no direct morphologic transitions
between EmGD and well-developed ESC [76,79]. 4)
EmGD lesions display a proliferative and p53 staining
index that is at least intermediate between resting
endometrium and small ESC/serous EIC, which argues
strongly against their being reactive in nature 5) Differen-
tial patterns of LOH for selected DNA markers in EmGD,
ESC/serous EIC and resting endometrium indicates signif-
icant differences between EmGD and the resting
endometrium in which they were identified and a kinship
with ESC/serous EIC [77]. 6) EmGD was identified in
33% of the endometrial biopsies that preceded hysterec-
tomies with ESC at an average duration of 33 months, but
was present in only 3.4% of endometrial biopsies that pre-
ceded uteri with benign diagnoses [82]. Combined, these
Cytologic features of serous endometrial glandular dysplasia (S-EmGD, 2 arrows), as compared with resting endometrium (RE,  1 arrow) and the so-called serous endometrial intraepithelial carcinoma (S-EIC, 3 arrows) Figure 1
Cytologic features of serous endometrial glandular dysplasia (S-EmGD, 2 arrows), as compared with resting endometrium (RE, 
1 arrow) and the so-called serous endometrial intraepithelial carcinoma (S-EIC, 3 arrows).
RE S-EmGD
S-EIC S-EmGDDiagnostic Pathology 2008, 3:6 http://www.diagnosticpathology.org/content/3/1/6
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data provide evidence that EmGD is the most likely pre-
cursor lesion for ESC. EmGD fulfils most of the National
Cancer Institute (NCI)'s criteria for a precancerous lesion
[33]: (1) there is preliminary evidence that EmGD is asso-
ciated with an increased risk of ESC; (2) partial molecular
concordance in p53 mutations between EmGD and ESC
provides one line of evidence that suggests that the latter
arises from the former; (3) EmGD differs from the normal
tissue from which it arises, and is morphologically recog-
nizable as such; (4) EmGD is morphologically distinct
from ESC, being characterized by cells that although more
atypical than the background endometrial cells, cannot be
characterized as cytologically malignant. (5) It is diagnos-
able by morphologic evaluation, with judicious use of
immunohistochemical adjuncts such as p53, Ki67 and
IMP3 in equivocal cases.
Nevertheless, it is unclear if EmGD represents an obligate
precursor, or whether it is reversible. At the present time,
however, we strongly advocate the discontinuation of the
routine usage of the diagnostic terms "EIC" or "serous
EIC". Small localized glandular or surface endometrial
foci that are lined by malignant cells of the "serous-type"
should simply be referred to as ESC, along with the size
and if possible location of the lesion, as others have pre-
viously suggested [97].
Clear cell endometrial glandular dysplasia
Endometrial clear cell carcinoma (ECCC), a Type II cancer
under the dualistic model, represents 1–5.5% of endome-
trial cancers [97,101-107]. Given the significant overlap
that exists between ECCC and ESC in their morphologic
[24,32], clinical [108] and global gene expression [109]
attributes, it can be anticipated that an in situ lesion prob-
ably exists for ECCC. However, in contrast to the cervix,
where sporadic examples of clear cell in situ lesions have
long been reported [110-112], very little had been pub-
lished on putative precursor lesions for ECCC until
recently [86,87]. In 2004, Moid and Berezowski [86]
described a distinctive lesion in the hysterectomy speci-
men of a 70-year-old woman which they designated "EIC,
clear cell type". The lesion was comprised of surface epi-
thelium and some glands that were lined by cells with
"clear cytoplasm, marked nuclear pleomorphism, coarse
chromatin, irregular nuclear membranes, and prominent
eosinophilic nucleoli" and which occasionally had a hob-
nail appearance. The lesions showed "focal" staining for
p53, a "moderate to high proliferative index", and no evi-
dence of extrauterine extension [86]. Recently, our group
attempted to more systematically characterize the clinico-
pathologic features of these putative precursor lesions. We
evaluated the adjacent benign endometria in 14 cases of
pure ECCC and 16 endometrial carcinomas with a greater
than 10% ECCC component, in search of lesions that
notably stood out from the background benign
endometrium [87]. The lesions that we identified were
single glands, small glandular clusters or segments of sur-
face endometrium lined by cells that typically displayed
cytoplasmic clarity and/or eosinophilia and a continuous
gradient of nuclear atypicality. Based on the severity of the
nuclear changes, we graded the lesions on a 3-tiered scale,
with the grade 3 lesions essentially being lined by frankly
malignant cells comparable to those of the adjacent
malignancies. Morphologically, grade 3 lesions were
essentially identical to clear cell EIC, while grade 1 and 2
lesions were designated clear cell EmGD (Figure 2). We
Resting endometrium (1 arrow); clear cell endometrial glandular dysplasia (clear cell-EmGD, 2 arrows); clear cell endometrial  intraepithelial carcinoma (clear cell-EIC, 3 arrows) Figure 2
Resting endometrium (1 arrow); clear cell endometrial glandular dysplasia (clear cell-EmGD, 2 arrows); clear cell endometrial 
intraepithelial carcinoma (clear cell-EIC, 3 arrows).Diagnostic Pathology 2008, 3:6 http://www.diagnosticpathology.org/content/3/1/6
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tentatively considered these lesions the putative precan-
cerous lesions for ECCC and proceeded to characterize
their phenotype. At least one such putative precancer
could be identified in 27 of the 30 cases evaluated, with
an average of 2.5 foci per case [87]. Immunohistochemi-
cal p53 scores (0–9 scale) for these precancers were on
average (4.5) lesser than the adjacent carcinomas (6.2)
but significantly greater than the benign endometria (0).
Similarly, the average proliferative index for the clear cell
precancers (45%) was intermediate between the carcino-
mas (63%) and benign endometria (15%). The lesions
also showed notably reduced expression of ER and PR as
compared with the adjacent benign endometria [87]. This
composite of morphologic and immunophenotypic fea-
tures resulted in lesions that were notably distinct from
the background benign endometrium. In the control
group of 38 benign uteri and 30 uteri with endometrioid
cancers, no single immunohistochemically-confirmed
clear cell precancer was identified [87]. Given their high
rate of association with carcinomas having a clear cell
component, their lack thereof in the control group of
endometrioid cancers, their frequent occurrence in other-
wise benign endometria and their aforementioned phe-
notype, we hypothesized that these lesions represent the
precursor lesions of ECCC [87]. It is acknowledged, how-
ever, that significantly more research is required to define
the full clinicopathologic spectrum of these distinctive
lesions and to establish their precancerous nature accord-
ing to NCI criteria [33].
Summary
Endometrial carcinomas are remarkably diverse in their
biologic behavior. Perhaps more so than other organ sys-
tems, the histotype designation alone (endometrioid,
serous, clear cell etc) provides a substantial amount of
prognostic information. The present nomenclature for
putative precursor lesions of endometrial cancers
describes an incoherent amalgam that encompasses a
lesion with very little malignancy risk (simple hyperplasia
without atypia), and on the other end of the "spectrum",
serous EIC, a lesion with inherent potential malignancy.
Upon superficial inspection, this seems to rightfully mir-
ror the biologic diversity of the invasive cancers for which
they probably represent progenitors. However, a critical
appraisal quickly reveals that at least a subset of the varia-
bility in the malignant potential of these precursors is
attributable to definitional problems. Most importantly,
as we have previously noted, we believe that the terms
"EIC" or "Serous EIC" should be discarded as a means to
describe an intraepithelial precancer. These lesions can
show extrauterine spread and should thus be considered
small uterine serous cancers. None of the other putative
endometrial precancers have been reported to show extra-
uterine spread when present in isolation. For ESCs, we
have presented morphologic, immunophenotypic,
molecular and follow-up data that strongly suggests that
EmGD represents their most probable precancerous
lesion. EmGD fulfils most of the NCI requirements for a
precancerous lesion [33]. For endometrial clear cell carci-
nomas, we similarly presented morphologic and immu-
nophenotypic data that suggests that EmGD of the clear
cell type represents their precancerous lesion, although
there is insufficient data at present time to conclusively
establish their precancerous nature by NCI standards.
Much is unknown about the nature, morphologic spec-
trum and clinical significance of endometrial precancers.
However, their eventual characterization will likely start
from their morphologic recognition. As such, the lesions
described herein are worthy of segregation by pathologists
and further study.
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